GT Biopharma, Inc. (GTBP)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN Summary
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
What made GT Biopharma stock more than double on Monday?
GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn't been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company.
Why Is GT Biopharma (GTBP) Stock Up 143% Today?
GT Biopharma (NASDAQ: GTBP ) stock is soaring higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 10.6 million shares of GTBP stock changing hands as of this writing.
GT Biopharma, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CGL Chester Gary Lloyd Coston, McIsaac & Partners | 17,092 | $13,417.22 | $7,349.56 | -$6,067.66 | -45.22% |
 Christopher C. Powers Farther Finance Advisors, LLC | 3,000 | $2,356 | $1,290 | -$1,066 | -45.25% |
GT Biopharma, Inc. (GTBP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has GT Biopharma, Inc. ever had a stock split?
GT Biopharma, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael Martin Breen CEO | NASDAQ (CM) Exchange | 36254L209 CUSIP |
| US Country | 1 Employees | - Last Dividend | 5 Feb 2024 Last Split | 22 Sep 2017 IPO Date |
Overview
GT Biopharma, Inc. stands as a pioneering force in the realm of biopharmaceuticals, focusing its efforts predominantly on the advancement and commercialization of innovative immuno-oncology therapies. Operating on the cutting-edge of medical research, the company prides itself on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. This technology signifies a revolutionary approach in the fight against cancer, showcasing GT Biopharma's commitment to leading the charge in oncological innovation. The inception of the company traces back to 1965, originally known as OXIS International, Inc., before rebranding to GT Biopharma, Inc. in July 2017. Based in Brisbane, California, GT Biopharma continues to forge partnerships and license agreements to bolster its developmental capabilities, including noteworthy collaborations with Altor BioScience Corporation and the Regents of the University of Minnesota.
Products and Services
- GTB-3550: This flagship product of GT Biopharma, Inc. represents a significant stride in the battle against hematologic malignancies. GTB-3550 is a single-chain tri-specific recombinant fusion protein conjugate, currently undergoing a Phase I clinical trial. It targets the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia, advanced systemic mastocytosis, and CD33+ malignancies. The innovative nature of GTB-3550 underscores GT Biopharma's dedication to confronting some of the most challenging cancer types.
- GTB-3650: Still in the realm of preclinical studies, GTB-3650 underscores the company’s ongoing efforts to extend its TriKE technology's reach. This investigational therapy aims to specifically target CD33 on the surface of myeloid leukemias, reflecting a targeted approach in the treatment and understanding of this particular cancer type.
- GTB-5550: Similar to GTB-3650 but with a distinct focus, GTB-5550 is tailored for the treatment of B7-H3 positive solid tumors. Currently under preclinical study, GTB-5550 symbolizes the breadth of GT Biopharma's research endeavors, working to extend the efficacious principles of its TriKE technology across a wide array of cancers, thereby promising a hopeful future for patients with solid tumors.
